Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): After conducting checks, Oppenheimer believes there is a good chance that Phase III tests of Rigel Pharmaceuticals, Inc.’s Fostamatinib for Rheumatoid Arthritis will yield successful results. They believe that the stock only reflects a 35% chance of successful Phase III data and raised their target on the shares from $12 to $15 while maintaining an Outperform rating.
Cisco Systems, Inc. (NASDAQ:CSCO): Cisco believes that a slowdown in United States enterprise spending will cause Cisco Systems, Inc. to report weaker than expected results for their October quarter. However, the firm said that the company is executing in a weak environment and they maintain an Outperform rating.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Devon Energy Corporation (NYSE:DVN): FBR Capital believes that investor sentiment is too negative regarding Devon Energy Corporation’s near- and long-term outlooks. They view the stock as a deep value play and reiterate an Outperform rating on the name with an $80 price target.
SM Energy Company (NYSE:SM): Oppenheimer believes that SM Energy Company’s third quarter results will boost investors’ confidence in their 2013 outlook and the firm continues to think that their stock is attractive at current levels. Oppenheimer maintains an Outperform rating on their shares.
Zillow Inc (NASDAQ:Z): After the company’s fourth quarter outlook missed expectations, Citigroup lowered their price target for Zillow Inc. shares from $46 to $35 but reiterates a Buy rating on their stock. Citi believes Zillow remains poised for solid growth and that their fundamentals still look solid.
Don’t Miss: Did the Roof Just Cave in on Zillow?